Venus Remedies Limited (BOM:526953)
762.45
+17.40 (2.34%)
At close: Feb 12, 2026
Venus Remedies Revenue
Venus Remedies had revenue of 1.80B INR in the quarter ending December 31, 2025, with 1.92% growth. This brings the company's revenue in the last twelve months to 7.03B, up 8.45% year-over-year. In the fiscal year ending March 31, 2025, Venus Remedies had annual revenue of 6.48B with 7.72% growth.
Revenue (ttm)
7.03B
Revenue Growth
+8.45%
P/S Ratio
1.41
Revenue / Employee
5.41M
Employees
1,298
Market Cap
9.88B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 6.48B | 464.37M | 7.72% |
| Mar 31, 2024 | 6.01B | 459.40M | 8.27% |
| Mar 31, 2023 | 5.56B | -446.71M | -7.44% |
| Mar 31, 2022 | 6.00B | 520.57M | 9.50% |
| Mar 31, 2021 | 5.48B | 2.07B | 60.90% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| TTK Healthcare | 8.30B |
| Anuh Pharma | 7.68B |
| Wanbury | 6.58B |
| Lincoln Pharmaceuticals | 6.32B |
| Kopran | 6.20B |
| Fredun Pharmaceuticals | 5.91B |
| Fermenta Biotech | 5.44B |
| Syncom Formulations (India) | 5.15B |